PYRIDONE DERIVATIVES USED AS INHIBITORS OF REARRANGED KINASE DURING TRANSFECTION (RET)

Abstract

The present invention relates to novel compounds that are inhibitors of transfection rearranged kinase (RET), pharmaceutical compositions containing them, methods for their preparation, and their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity. Disorders of motility and / or secretion and / or the abdomen and / or treatments associated with conditions related to RET dysfunction or in which modulation of RET activity may have a therapeutic benefit, including, without limitation, all classifications of irritable bowel syndrome (IBS), including diarrhea-dominant stools, predominantly or alternating constipation, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorders, functional abdominal pain syndrome, and chronic idiopathic constipation.functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, progressive bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancers, head and neck cancers, gliomas, neuroblastomas, von Hippel-Lindau syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell carcinoma, prostate cancer, esophageal and gastroesophageal junction cancer, bile duct cancer, adenocarcinoma and any cancer with increased ret kinase activity.